Trial reportLeukemia & lymphoma2020
Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
Registry-linked trialOpen access · hybridAbstract readClinical Trial, Phase IIIRandomized Controlled Trial
In one paragraph
Trial report in Leukemia & lymphoma, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01611090 (Randomized, Double-blind, Placebo-controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase), which is not on this map. Cited by 29 papers, 4 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 4 pooled it
3.3field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Randomized, Double-blind, Placebo-controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Combination With Bendamustine and Rituximab (BR) in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Who cites it
29 citing papers in PubMed, 4 syntheses or guidelines pooled it, 43 citations in OpenAlex.
- Invasive fungal infections after Bruton tyrosine kinase inhibitor treatment: a systematic review and meta-analysis.Blood advances · 2026Pooled it
- Venetoclax Plus Rituximab for Relapse/Refractory Chronic Lymphocytic Leukemia: A Systematic Review and Network Meta-analysis of Treatments Available in Brazil.Oncology and therapy · 2026Pooled it
- Real world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: a meta-analysis of clinical studies.BMC pharmacology & toxicology · 2025Pooled it
- Systematic Literature Review of Real-World Effectiveness Results Data for First-Line Ibrutinib in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma.Drugs - real world outcomes · 2023Pooled it
- Statin use and survival in CLL/SLL treated with ibrutinib: pooled analysis of 4 randomized controlled trials.Blood advances · 2025Trial
- Pooled safety analysis of zanubrutinib monotherapy in Asian patients with B-cell malignancies.ESMO open · 2026Article
- Prognostic value of patient-reported outcome thresholds on survival and adverse events in CLL/SLL: A pooled analysis of ibrutinib trials.Therapeutic advances in hematology · 2026Article
- The role of MRD monitoring and options for CLL management in relapsed/refractory disease.Hematology. American Society of Hematology. Education Program · 2025Review
- Article
- A comparison of healthcare resource utilization and costs between patients with chronic lymphocytic leukemia treated with first-line ibrutinib or acalabrutinib using two large US real-world databases.Journal of comparative effectiveness research · 2025Article
- BTK inhibitors and next-generation BTK-targeted therapeutics for B-cell malignancies.Archives of pharmacal research · 2025Review
- Ibrutinib oral suspension bioavailability and compatibility for optimal enteral administration route.Therapeutic advances in hematology · 2025Article
- Network meta-analysis of novel targeted therapies for relapsed/refractory chronic lymphocytic leukemia.Therapeutic advances in medical oncology · 2024Article
- Comparative safety of novel targeted therapies in relapsed/refractory chronic lymphocytic leukemia: a network meta-analysis.Therapeutic advances in medical oncology · 2024Article
- Incidence of major bleeding in patients with chronic lymphocytic leukemia receiving ibrutinib and therapeutic anticoagulation.Leukemia & lymphoma · 2023Article
- Diagnosis and Management of Cardiovascular Effects of Bruton's Tyrosine Kinase Inhibitors.Current cardiology reports · 2023Review
- B-cell Receptor Pathway Mutations Are Infrequent in Patients with Chronic Lymphocytic Leukemia on Continuous Ibrutinib Therapy.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Article
- Measurable Residual Disease in Chronic Lymphocytic Leukemia: Current Understanding and Evolving Role in Clinical Practice.Current treatment options in oncology · 2023Review
- Managing Ibrutinib-Intolerant Patients With B-Cell Malignancies.The oncologist · 2023Review
- Oral formulation of bendamustine hydrochloride for patients with advanced solid tumors; a phase 1 study.Investigational new drugs · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors at 19 institutions in 13 countries.
Graeme A M FraserJuravinski Cancer Centre, McMaster University, Hamilton, Canada.
Asher Chanan-KhanDivision of Hematology, Mayo Clinic Cancer Center, Jacksonville, FL, USA.
Fatih DemirkanDivision of Hematology, Dokuz Eylul University, Izmir, Turkey.
Rodrigo Santucci SilvaIEP São Lucas/Hemomed Oncologia e Hematologia, São Paulo, Brazil.
Sebastian GrosickiDepartment of Hematology and Cancer Prevention, School of Public Health, Silesian Medical University, Katowice, Poland.
Ann JanssensUniversitaire Ziekenhuizen Leuven, Leuven, Belgium.
Jiri MayerDepartment of Internal Medicine, Hematology and Oncology, University Hospital Brno, Jihlavska, Brno, Czech Republic.
Nancy L BartlettSiteman Cancer Center, Washington University School of Medicine, St. Louis, MO, USA.ORCID 0000-0001-8470-394X
Marie-Sarah DilhuydyHopital Haut Leveque, Bordeaux, France.
Javier LoscertalesHematology Department, Hospital Universitario La Princesa, IIS-IP, Madrid, Spain.
Abraham AvigdorDivision of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel-Hashomer and Sackler School of Medicine, University of Tel-Aviv, Tel-Aviv, Israel.
Simon RuleDepartment of Haematology, University of Plymouth Medical School, Plymouth, UK.ORCID 0000-0001-8937-6351
Olga SamoilovaNizhny Novogorod Regional Clinical Hospital, Nizhny Novogorod, Russia.
Miguel A PavlovskyDepartment of Hematology, Fundaleu, Buenos Aires, Argentina.
Andre GoyJohn Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA.
Anthony MatoMemorial Sloan-Kettering Cancer Center, NY, USA.
Michael HallekDepartment I of Internal Medicine and German CLL Study Group, University of Cologne, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany.
Mariya SalmanJanssen Research & Development, Raritan, NJ, USA.
Monelle TamegnonJanssen Research & Development, Raritan, NJ, USA.
Steven SunJanssen Research & Development, Raritan, NJ, USA.
Anne ConnorJanssen Research & Development, Spring House, PA, USA.
Kerri NottageJanssen Research & Development, Raritan, NJ, USA.
Natasha SchuierJanssen-Cilag, Neuss, Germany.
Sriram BalasubramanianJanssen Research & Development, Spring House, PA, USA.
Angela HowesJanssen Research & Development, High Wycombe, UK.
Paula CramerDepartment I of Internal Medicine and German CLL Study Group, University of Cologne, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany.
Janssen (United States) · USUniversity of Cologne · DEDokuz Eylül University · TRFundación para la Investigación, Docencia y Prevención del Cáncer · ARHackensack University Medical Center · USHôpital Cardiologique du Haut-Lévêque · FRHospital Universitario de La Princesa · ESJanssen (Germany) · DEJanssen (United Kingdom) · GBJuravinski Cancer Centre · CAMedical University of Silesia · PLMemorial Sloan Kettering Cancer Center · USNizhny Novgorod Regional Clinical Hospital named after Semashko · RUSheba Medical Center · ILUniversitair Ziekenhuis Leuven · BEUniversity Hospital Brno · CZUniversity of Plymouth · GBWashington University in St. Louis · USWinnMed · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MNCI NIH HHS P30 CA008748
Abstract
We report final analysis outcomes from the phase 3 HELIOS study (NCT01611090). Patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma without deletion 17p (
Indexed as
Leukemia, Lymphocytic, Chronic, B-CellAdenineAntineoplastic Combined Chemotherapy ProtocolsBendamustine HydrochlorideHumansPiperidinesRituximabAdenineBendamustine HydrochlorideibrutinibPiperidinesRituximab5-year follow-upHELIOS phase 3 trialIbrutiniboverall survivalrelapsed chronic lymphocytic leukemia
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
NCT01611090ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.